What interacts with DXM?
Find a substance to learn about the hazards of combining it with dextromethorphan (DXM) and the supporting evidence.
No exact match. Did you mean:
The search index could not be loaded. Alphabetic index
Search index version mismatch. Alphabetic index
Or choose a substance group
PHI is a provisional hazard rating for a combination with DXM on a 0–10 scale.
MAO inhibitors
- No PHI rating
Why is there no PHI rating?
Full explanation from the review
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
Antidepressants
- No PHI rating
Why is there no PHI rating?
The review gives this DXM combination no PHI. Mirtazapine, buspirone, triptans and cyclobenzaprine differ in pharmacology and main concerns.
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
Also belongs to this group
Antihistamines and antiemetics
- No PHI rating
Why is there no PHI rating?
Full explanation from the review
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
Other agents and products — Lithium, St John’s wort, 5-HTP
- No PHI rating
Why is there no PHI rating?
The review leaves PHI unassigned for DXM with 5-HTP because data for a numerical comparison are insufficient.
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
- No PHI rating
Why is there no PHI rating?
The review gives this DXM combination no PHI. Mirtazapine, buspirone, triptans and cyclobenzaprine differ in pharmacology and main concerns.
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
- No PHI rating
Why is there no PHI rating?
A combination medicine contains DXM and other active ingredients. Acetaminophen, chlorphenamine, sedating antihistamines and sympathomimetic decongestants can cause their own toxic effects as more of the product is taken. Most cards assess DXM with one other substance; a combination medicine requires accounting for all its ingredients [6, 7, 25]. Extended release also changes how long the substances act together.
Full explanation from the review
DXM alone must be distinguished from combination medicines. Acetaminophen (paracetamol), chlorphenamine, sedating antihistamines, and sympathomimetic decongestants can create their own toxicity when more of the product is taken. These ingredients place the product outside most two-substance rows [6, 7, 25]. Extended-release formulations also alter the duration of overlapping effects.
- No PHI rating
Why is there no PHI rating?
The review gives this DXM combination no PHI. Mirtazapine, buspirone, triptans and cyclobenzaprine differ in pharmacology and main concerns.
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
- No PHI rating
Why is there no PHI rating?
Alkaloid concentrations in Datura and Atropa belladonna vary, so the amount of plant material does not reliably indicate the amount of active substances. The review excludes these plants from numerical PHI scoring because that scoring assumes a known exposure to the active substance [35].
Full explanation from the review
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
- No PHI rating
Why is there no PHI rating?
The review leaves PHI unassigned for DXM with lithium because data for a numerical comparison are insufficient.
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
- No PHI rating
Why is there no PHI rating?
Piracetam, DMAE, and lecithin are excluded from the numerical matrix. The FAQ contains accounts of subjective memory improvement, but evidence is insufficient to treat them as protection against physical injury.
- No PHI rating
Why is there no PHI rating?
Full explanation from the review
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
- No PHI rating
Why is there no PHI rating?
The review leaves PHI unassigned for DXM with St John’s wort because data for a numerical comparison are insufficient. ACMT lists St John’s wort as a possible interacting agent, without a numerical estimate for this pair [25].
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
- No PHI rating
Why is there no PHI rating?
Triptans differ in pharmacology; the review leaves PHI unassigned for their DXM combinations. ACMT lists triptans as possible interacting agents, without numerical estimates for individual pairs [25].
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
- No PHI rating
Why is there no PHI rating?
The review leaves PHI unassigned for DXM with tryptophan because data for a numerical comparison are insufficient.
Full explanation from the review
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
The US label for Robitussin Long-Acting CoughGels lists dextromethorphan hydrobromide (DXM). For “Robitussin DM CoughGels”, check the exact product name and active ingredients on its label.
Find combinations by mechanism
Choose a mechanism to see all combinations linked to it.
- Serotonin-related — 32 combinations
- Cardiovascular and thermal — 24 combinations
- Sedation and respiration — 27 combinations
- Metabolism — 16 combinations
- NMDA — 5 combinations
- Antimuscarinic — 6 combinations
- Seizure-related concern — 4 combinations
- Other discussed pathways — 5 combinations
Map and table by substance group
Substance groups and mechanisms
70 PHI-rated entries
Each marker counts family entries with group tags.
List: exact links and counts
MAO inhibitors · 7
Antidepressants · 7
Stimulants · 10
Opioids and opioid-like agents · 9
Other depressants · 9
Dissociatives · 5
Psychedelics · 8
Cannabinoids · 2
Antihistamines and antiemetics · 7
Other metabolic modifiers · 6
MAO inhibitors · 8
All primary entries in this family. Right-hand counts are entries with group tags.
- Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changaMAOPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methylene bluePHI 8 to 9MAO
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MoclobemidePHI 8 to 9MAO / 2D6
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Overdose data; they do not show outcome frequency at ordinary exposures.
- Other reversible MAO-A inhibitorsMAOPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Phenelzine, tranylcypromine, isocarboxazidMAOPHI 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Selegiline or rasagilineMAOPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - LinezolidPHI 6 to 8MAO
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe study did not find the effect it tested for.
Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations.
These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.
Result in the interaction cardCurrent linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40].
- Selegiline, rasagiline, and safinamideNo PHI ratingMechanism not identified in the review
Antidepressants · 8
All primary entries in this family. Right-hand counts are entries with group tags.
- Clomipramine and other tricyclic antidepressants (TCAs)SERT / AM / CARDPHI 6 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DuloxetinePHI 6 to 8SERT / 2D6 / SYM
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Fluoxetine, paroxetineSERT / 2D6PHI 7 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - NefazodonePHI 5 to 7SERT / 5HT-R / 3A
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Sertraline, escitalopram, citalopram, fluvoxamineSERTPHI 6 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Venlafaxine, desvenlafaxineSERT / SYMPHI 6 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - TrazodonePHI 4 to 6SERT / 5HT-R / SED
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MirtazapineNo PHI ratingMechanism not identified in the review
Stimulants · 10
All primary entries in this family. Right-hand counts are entries with group tags.
- MDA, serotonergic cathinones, and other serotonergic releasersREL / SYMPHI 7 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MDMAPHI 8 to 9REL / 2D6 / SYM
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- CocainePHI 6 to 8SYM / SERT
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MethamphetaminePHI 6 to 8SYM / REL
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Amphetamine, dextroamphetamineSYM / REL?PHI 5 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MethylphenidatePHI 4 to 6SYM
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - YohimbinePHI 4 to 6SYM
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Pseudoephedrine, phenylephrineSYMPHI 3 to 5
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - CaffeinePHI 1 to 3SYM
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - NicotinePHI 1 to 3SYM
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Opioids and opioid-like agents · 9
All primary entries in this family. Right-hand counts are entries with group tags.
- Pethidine (meperidine)PHI 7 to 9OP / SERT / SEIZ
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - TramadolPHI 7 to 9OP / SERT / SEIZ
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - FentanylPHI 6 to 8OP / SED / 5HT-R?
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MethadonePHI 7 to 8OP / SERT / 2D6 / CARD
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Morphine, hydromorphone, oxycodone, heroinOP / SEDPHI 5 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - TapentadolPHI 5 to 7OP / SERT / SYM
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - BuprenorphinePHI 4 to 6OP / SED
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - CodeinePHI 4 to 6OP / SED / 2D6
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Kratom (Mitragyna speciosa)PHI 3 to 5OP? / SED / 3A?
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
The study did not find the effect it tested for.
In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe.
Result in the interaction cardUnder the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].
Other depressants · 9
All primary entries in this family. Right-hand counts are entries with group tags.
- Barbiturates, including phenobarbital and pentobarbitalSEDPHI 6 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - GHB, GBL, 1,4-butanediolSEDPHI 6 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Amanita muscaria or Amanita pantherinaSEDPHI 5 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - EthanolPHI 4 to 6SED
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MuscimolPHI 4 to 6SED
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Phenibut, baclofenSEDPHI 4 to 6
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Pregabalin, gabapentinSEDPHI 4 to 6
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Benzodiazepines, including alprazolam, diazepam, clonazepamSEDPHI 3 to 5
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Zolpidem, zopiclone, and other Z-drugsSEDPHI 3 to 5
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Dissociatives · 5
All primary entries in this family. Right-hand counts are entries with group tags.
- MXE and other ketamine analoguesNMDA / MONO?PHI 4 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - PCP, 3-MeO-PCP, 3-HO-PCP, and related compoundsNMDA / SYMPHI 5 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - KetaminePHI 4 to 6NMDA / SED / SYM
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MemantinePHI 3 to 5NMDA
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Nitrous oxidePHI 3 to 5NMDA / HYPOX / B12
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Psychedelics · 8
All primary entries in this family. Right-hand counts are entries with group tags.
- NBOMe compounds, including 25I, 25B, 25C5HT-R / SYM / SEIZPHI 6 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - 5-MeO-DMTPHI 4 to 65HT-R / SED
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DOx compounds, including DOM, DOB, DOC5HT-R / SYMPHI 4 to 6
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - 2C-BPHI 2 to 45HT-R / SYM
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DMTPHI 2 to 45HT-R / SYM
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MescalinePHI 2 to 45HT-R / SYM
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - LSD, psilocybin, psilocin5HT-RPHI 1 to 3
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Salvinorin A (Salvia divinorum)KOR / IMPPHI 1 to 3
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Cannabinoids · 2
All primary entries in this family. Right-hand counts are entries with group tags.
- THC-dominant cannabisPHI 2 to 4CB / SYM / IMP
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - CBD-dominant productsPHI 1 to 3CYP / CB
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
The study did not find the effect it tested for.
In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6.
Result in the interaction cardA CBD-dominant product is not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].
Antihistamines and antiemetics · 8
All primary entries in this family. Right-hand counts are entries with group tags.
- Chlorphenamine (chlorpheniramine)PHI 6 to 7SERT / AM / SED
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOverdose data; they do not show outcome frequency at ordinary exposures.
- Diphenhydramine, dimenhydrinate, doxylamineAM / SED / 2D6?PHI 4 to 6
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - ScopolaminePHI 4 to 6AM / SED
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Cyclizine, meclizine, hydroxyzineAM / SEDPHI 3 to 5
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - PromethazinePHI 3 to 5AM / SED
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Loratadine, desloratadine, cetirizineSED?PHI 1 to 3
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - FexofenadinePHI 1 to 2Mechanism not identified in the review
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - OndansetronNo PHI ratingMechanism not identified in the review
Other metabolic modifiers · 6
All primary entries in this family. Right-hand counts are entries with group tags.
- QuinidinePHI 6 to 82D6 / CARD
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- BupropionPHI 5 to 72D6 / SEIZ
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Other strong CYP3A inhibitors, including cobicistat, azoles, clarithromycin3APHI 3 to 6
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - RitonavirPHI 3 to 63A / 2D6
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- TerbinafinePHI 4 to 62D6
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Grapefruit and Seville orange juice3APHI 2 to 4
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Other agents and products · 11
All primary entries in this family. Right-hand counts are entries with group tags.
- 5-HTPNo PHI ratingMechanism not identified in the review
- buspironeNo PHI ratingMechanism not identified in the review
- Combination medicines containing acetaminophen (paracetamol)No PHI ratingMechanism not identified in the review
- cyclobenzaprineNo PHI ratingMechanism not identified in the review
- Datura and Atropa belladonnaNo PHI ratingMechanism not identified in the review
- LithiumNo PHI ratingMechanism not identified in the review
- Piracetam, DMAE, and lecithinNo PHI ratingMechanism not identified in the review
- QT-prolonging drugsNo PHI ratingMechanism not identified in the review
- St John’s wortNo PHI ratingMechanism not identified in the review
- triptansNo PHI ratingMechanism not identified in the review
- tryptophanNo PHI ratingMechanism not identified in the review
Highlighted lines show structured links; dashed lines have only uncertain tags. PHI ratings are given in the combination entries.
No PHI rating · 14Combinations by mechanism
Choose a category to see PHI-rated combinations. The numbers show how many combinations are in each list.
Non-empty cells: 35 of 80.
How to read the table
0 means the category is not marked in the review. ? N means the mechanism’s contribution is uncertain for N combinations. A combination may appear in several columns; it is counted once in the overall total.
Antidepressants: 7 entries
Stimulants: 10 entries
Opioids and opioid-like agents: 9 entries
Dissociatives: 5 entries
Psychedelics: 8 entries
Cannabinoids: 2 entries
Antihistamines and antiemetics: 7 entries
Other metabolic modifiers: 6 entries
Total rated entries
- Serotonin-related: 32 entries
- Cardiovascular and thermal: 24 entries
- Sedation and respiration: 27 entries
- Metabolism: 16 entries
- NMDA: 5 entries
- Antimuscarinic: 6 entries
- Seizure-related concern: 4 entries
- Other discussed pathways: 5 entries
Total: 70 rated entries
- 0
- 5
- 10
Expand a substance group to see its coloured counts.
Total: 70 rated entries
MAO inhibitors × Serotonin-related · 7
- Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changa
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methylene blue, intravenous
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Moclobemide
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Overdose data; they do not show outcome frequency at ordinary exposures.
- Other reversible MAO-A inhibitors
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Phenelzine, tranylcypromine, isocarboxazid
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Selegiline or rasagiline, when MAO-B selectivity is lost
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Linezolid
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe study did not find the effect it tested for.
Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations.
These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.
Result in the interaction cardCurrent linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40].
MAO inhibitors × Cardiovascular and thermal · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageMAO inhibitors × Sedation and respiration · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageMAO inhibitors × Metabolism · 1
- Moclobemide
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Overdose data; they do not show outcome frequency at ordinary exposures.
MAO inhibitors × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageMAO inhibitors × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageMAO inhibitors × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageMAO inhibitors × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageAntidepressants × Serotonin-related · 7
- Clomipramine and other tricyclic antidepressants (TCAs)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Duloxetine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Fluoxetine, paroxetine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Nefazodone
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Sertraline, escitalopram, citalopram, fluvoxamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Venlafaxine, desvenlafaxine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Trazodone
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antidepressants × Cardiovascular and thermal · 3
- Clomipramine and other tricyclic antidepressants (TCAs)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Duloxetine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Venlafaxine, desvenlafaxine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antidepressants × Sedation and respiration · 1
- Trazodone
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antidepressants × Metabolism · 3
- Duloxetine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Fluoxetine, paroxetine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Nefazodone
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antidepressants × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageAntidepressants × Antimuscarinic · 1
- Clomipramine and other tricyclic antidepressants (TCAs)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antidepressants × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageAntidepressants × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageStimulants × Serotonin-related · 5
- MDA, serotonergic cathinones, and other serotonergic releasers
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MDMA
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Cocaine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methamphetamine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Amphetamine, dextroamphetamine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Stimulants × Cardiovascular and thermal · 10
- MDA, serotonergic cathinones, and other serotonergic releasers
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - MDMA
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Cocaine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methamphetamine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Amphetamine, dextroamphetamine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methylphenidate
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Yohimbine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Pseudoephedrine, phenylephrine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Caffeine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Nicotine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Stimulants × Sedation and respiration · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageStimulants × Metabolism · 1
- MDMA
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Stimulants × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageStimulants × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageStimulants × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageStimulants × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOpioids and opioid-like agents × Serotonin-related · 5
- Pethidine (meperidine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Tramadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Fentanyl
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methadone
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Tapentadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Opioids and opioid-like agents × Cardiovascular and thermal · 2
- Methadone
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Tapentadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Opioids and opioid-like agents × Sedation and respiration · 9
- Pethidine (meperidine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Tramadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Fentanyl
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Methadone
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Morphine, hydromorphone, oxycodone, heroin
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Tapentadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Buprenorphine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Codeine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Kratom (Mitragyna speciosa)
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
The study did not find the effect it tested for.
In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe.
Result in the interaction cardUnder the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].
Opioids and opioid-like agents × Metabolism · 3
- Methadone
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Codeine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Kratom (Mitragyna speciosa)
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
The study did not find the effect it tested for.
In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe.
Result in the interaction cardUnder the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].
Opioids and opioid-like agents × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOpioids and opioid-like agents × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOpioids and opioid-like agents × Seizure-related concern · 2
- Pethidine (meperidine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Tramadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Opioids and opioid-like agents × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × Serotonin-related · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × Cardiovascular and thermal · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × Sedation and respiration · 9
- Barbiturates, including phenobarbital and pentobarbital
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - GHB, GBL, 1,4-butanediol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Amanita muscaria or Amanita pantherina
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Ethanol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Muscimol
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Phenibut, baclofen
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Pregabalin, gabapentin
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Benzodiazepines, including alprazolam, diazepam, clonazepam
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Zolpidem, zopiclone, and other Z-drugs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Other depressants × Metabolism · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther depressants × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageDissociatives × Serotonin-related · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageDissociatives × Cardiovascular and thermal · 2
- PCP, 3-MeO-PCP, 3-HO-PCP, and related compounds
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Ketamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Dissociatives × Sedation and respiration · 1
- Ketamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Dissociatives × Metabolism · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageDissociatives × NMDA · 5
- MXE and other ketamine analogues
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - PCP, 3-MeO-PCP, 3-HO-PCP, and related compounds
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Ketamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Memantine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Nitrous oxide
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Dissociatives × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageDissociatives × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageDissociatives × Other discussed pathways · 2
- MXE and other ketamine analogues
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Nitrous oxide
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Psychedelics × Serotonin-related · 7
- NBOMe compounds, including 25I, 25B, 25C
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - 5-MeO-DMT, without MAOIs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DOx compounds, including DOM, DOB, DOC
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - 2C-B
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DMT, without MAOIs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Mescaline
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - LSD, psilocybin, psilocin
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Psychedelics × Cardiovascular and thermal · 5
- NBOMe compounds, including 25I, 25B, 25C
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DOx compounds, including DOM, DOB, DOC
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - 2C-B
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - DMT, without MAOIs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Mescaline
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Psychedelics × Sedation and respiration · 1
- 5-MeO-DMT, without MAOIs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Psychedelics × Metabolism · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pagePsychedelics × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pagePsychedelics × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pagePsychedelics × Seizure-related concern · 1
- NBOMe compounds, including 25I, 25B, 25C
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Psychedelics × Other discussed pathways · 1
- Salvinorin A (Salvia divinorum)
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Cannabinoids × Serotonin-related · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageCannabinoids × Cardiovascular and thermal · 1
- THC-dominant cannabis
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Cannabinoids × Sedation and respiration · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageCannabinoids × Metabolism · 1
- CBD-dominant products
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
The study did not find the effect it tested for.
In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6.
Result in the interaction cardA CBD-dominant product is not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].
Cannabinoids × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageCannabinoids × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageCannabinoids × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageCannabinoids × Other discussed pathways · 2
- THC-dominant cannabis
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - CBD-dominant products
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
The study did not find the effect it tested for.
In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6.
Result in the interaction cardA CBD-dominant product is not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].
Antihistamines and antiemetics × Serotonin-related · 1
- Chlorphenamine (chlorpheniramine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOverdose data; they do not show outcome frequency at ordinary exposures.
Antihistamines and antiemetics × Cardiovascular and thermal · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageAntihistamines and antiemetics × Sedation and respiration · 6
- Chlorphenamine (chlorpheniramine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOverdose data; they do not show outcome frequency at ordinary exposures.
- Diphenhydramine, dimenhydrinate, doxylamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Scopolamine, with known active-substance exposure
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Cyclizine, meclizine, hydroxyzine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Promethazine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Loratadine, desloratadine, cetirizine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antihistamines and antiemetics × Metabolism · 1
- Diphenhydramine, dimenhydrinate, doxylamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method
Antihistamines and antiemetics × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageAntihistamines and antiemetics × Antimuscarinic · 5
- Chlorphenamine (chlorpheniramine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOverdose data; they do not show outcome frequency at ordinary exposures.
- Diphenhydramine, dimenhydrinate, doxylamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Scopolamine, with known active-substance exposure
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Cyclizine, meclizine, hydroxyzine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Promethazine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Antihistamines and antiemetics × Seizure-related concern · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageAntihistamines and antiemetics × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther metabolic modifiers × Serotonin-related · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther metabolic modifiers × Cardiovascular and thermal · 1
- Quinidine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Other metabolic modifiers × Sedation and respiration · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther metabolic modifiers × Metabolism · 6
- Quinidine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Bupropion
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Other strong CYP3A inhibitors, including cobicistat, azoles, clarithromycin
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
Method - Ritonavir, alone or in ritonavir-boosted regimens
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Terbinafine, oral
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
- Grapefruit and Seville orange juice
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Other metabolic modifiers × NMDA · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther metabolic modifiers × Antimuscarinic · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageOther metabolic modifiers × Seizure-related concern · 1
- Bupropion
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Other metabolic modifiers × Other discussed pathways · 0
There are no PHI-rated entries for this mechanism group here.
Open the list on the group pageHow to read PHI
PHI is a provisional hazard rating for a combination with DXM on a 0–10 scale.
Overlapping ranges: the ordering by hazard level remains uncertain
Method →Understand differences
Stories and diagrams with conditions, sources and limits.
Learn → Compare two combinations →FAQ update
29 claims · 10 topics. A selective audit of the historical FAQ.
Archive & laboratory →DXM + 2C-B
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodA psychedelic with autonomic effects.
5HT-R · SYM
Full combination description CompareDXM + 5-HTP
No PHI rating
The review leaves PHI unassigned for DXM with 5-HTP because data for a numerical comparison are insufficient.
DXM + 5-MeO-DMT
without MAOIs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodImpaired consciousness and possible serotonergic contribution; principally extrapolative rating [9]
5HT-R · SED
Full combination description CompareDXM + Combination medicines containing acetaminophen (paracetamol)
No PHI rating
A combination medicine contains DXM and other active ingredients. Acetaminophen, chlorphenamine, sedating antihistamines and sympathomimetic decongestants can cause their own toxic effects as more of the product is taken. Most cards assess DXM with one other substance; a combination medicine requires accounting for all its ingredients [6, 7, 25]. Extended release also changes how long the substances act together.
DXM + Amanita muscaria or Amanita pantherina
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMuscimol, ibotenic acid and variable composition. The source describes mushroom properties and toxicity; information on the DXM combination is limited [16].
SED
Full combination description CompareDXM + Amphetamine, dextroamphetamine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodBlood pressure, heart rate and temperature. A serotonin-related contribution is possible.
SYM · REL?
Full combination description CompareDXM + Barbiturates, including phenobarbital and pentobarbital
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMarked central nervous system and respiratory depression. Complication rate for this combination unknown [1]
SED
Full combination description CompareDXM + Benzodiazepines, including alprazolam, diazepam, clonazepam
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConcerns involve impaired consciousness, coordination and protective reflexes [1].
SED
Full combination description CompareDXM + Buprenorphine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOpioid sedation — drowsiness and reduced alertness. Concerns about the DXM combination remain even when individual effects reach a ceiling [5].
OP · SED
Full combination description CompareDXM + Bupropion
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodEstablished increase in DXM exposure. Its own seizure hazard [2]
2D6 · SEIZ
Full combination description CompareDXM + buspirone
No PHI rating
The review gives this DXM combination no PHI. Mirtazapine, buspirone, triptans and cyclobenzaprine differ in pharmacology and main concerns.
DXM + Caffeine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe main concerns involve heart rate and blood pressure.
SYM
Full combination description CompareDXM + CBD-dominant products
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDirect measurements of how the body processes substances come from a specific study. That study did not find marked inhibition of the CYP2D6 enzyme [10].
CYP · CB
Full combination description CompareDXM + Chlorphenamine (chlorpheniramine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodEffects on serotonin reuptake and anticholinergic effects. Poisonings involving combination products [6]
SERT · AM · SED
Full combination description CompareDXM + Cocaine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSympathetic stress, ischemia (insufficient blood supply), arrhythmias (disturbances of heart rate or rhythm), and effects on serotonin reuptake. This row has no reference; the review treats rows without a reference as provisional estimates based on pharmacological properties.
SYM · SERT
Full combination description CompareDXM + Codeine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodCYP2D6 converts codeine to morphine; morphine formation varies with CYP2D6 phenotype [54, 55]. The codeine label describes reduced morphine concentrations during CYP2D6 inhibition and warns of respiratory depression and sedation with other CNS depressants [54]. The clinical magnitude of its interaction with DXM remains uncertain.
OP · SED · 2D6
Full combination description CompareDXM + Cyclizine, meclizine, hydroxyzine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSedative and anticholinergic effects differ among these medicines. PHI applies to the group; the review provides no measured severity of complications for each individual DXM combination.
AM · SED
Full combination description CompareDXM + cyclobenzaprine
No PHI rating
The review gives this DXM combination no PHI. Mirtazapine, buspirone, triptans and cyclobenzaprine differ in pharmacology and main concerns.
DXM + Datura and Atropa belladonna
No PHI rating
Alkaloid concentrations in Datura and Atropa belladonna vary, so the amount of plant material does not reliably indicate the amount of active substances. The review excludes these plants from numerical PHI scoring because that scoring assumes a known exposure to the active substance [35].
DXM + Diphenhydramine, dimenhydrinate, doxylamine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDrowsiness, reduced alertness and anticholinergic effects. CYP2D6 inhibition is better supported for diphenhydramine. This means reduced activity of the enzyme. The supporting findings come from laboratory work and human interactions involving other substances; they do not allow the effect on DXM to be calculated [18].
AM · SED · 2D6?
Full combination description CompareDXM + DMT
without MAOIs
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodAcute autonomic effects and impairment. Little direct DXM evidence [8]
5HT-R · SYM
Full combination description CompareDXM + DOx compounds, including DOM, DOB, DOC
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodProlonged autonomic and vascular stress. PHI is the review’s comparative judgment; it provides no direct measurement of risk from the DXM combination.
5HT-R · SYM
Full combination description CompareDXM + Duloxetine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodInhibition of serotonin and noradrenaline reuptake, together with CYP2D6 inhibition. The review’s numerical PHI judgment rests on limited data for this combination [2].
SERT · 2D6 · SYM
Full combination description CompareDXM + Ethanol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDrowsiness, vomiting and vomit entering the airways. The review also mentions a hypothesis that this combination could protect nerve tissue; it provides no evidence confirming that hypothesis [1].
SED
Full combination description CompareDXM + Fentanyl
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodPrimarily its own respiratory depression. A separate serotonergic signal [5]
OP · SED · 5HT-R?
Full combination description CompareDXM + Fexofenadine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodNo substantial toxic mechanism of the pair identified. Direct proof of safety absent
DXM + Fluoxetine, paroxetine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSERT · 2D6
Full combination description CompareDXM + GHB, GBL, 1,4-butanediol
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodComa and respiratory failure. With GHB, progression to deep sedation can be abrupt as concentration increases [11]. The rating takes this property and potentially additive impairment of consciousness into account. Direct evidence of a specific DXM–GHB synergy is insufficient.
SED
Full combination description CompareDXM + Grapefruit and Seville orange juice
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodIn a study of healthy volunteers, grapefruit juice and Seville orange juice increased DXM bioavailability: a larger fraction of an oral dose reached the bloodstream unchanged [22]. What this means for health depends on how the body breaks down DXM. This drug-processing finding alone cannot predict the outcome for an individual.
3A
Full combination description CompareDXM + Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changa
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe concern with DXM and harmalas rests on MAO-A inhibition by their components [9]. DMT without MAOIs has its own entry.
MAO
Full combination description CompareDXM + Ketamine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe dissociative effects of DXM and ketamine can add together. Vomiting, impaired protective reflexes and blood-pressure concerns. Amplification beyond the combined effects of the two substances has not been measured [14].
NMDA · SED · SYM
Full combination description CompareDXM + Kratom (Mitragyna speciosa)
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodA study found no change in DXM metabolism after a single low exposure to kratom [29]. This result applies to the tested conditions; the study did not assess sedation, larger amounts or repeated use.
OP? · SED · 3A?
Full combination description CompareDXM + Linezolid
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodWeak, reversible inhibition of monoamine oxidase (MAO), an enzyme that breaks down monoamines. The review reports negative findings from controlled DXM testing at therapeutic exposure. These findings apply to the tested conditions. Concern under other conditions comes from the mechanism. AUVELITY labeling contraindicates use together [2, 39, 40].
MAO
Full combination description CompareDXM + Lithium
No PHI rating
The review leaves PHI unassigned for DXM with lithium because data for a numerical comparison are insufficient.
DXM + Loratadine, desloratadine, cetirizine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDrowsiness and reduced alertness vary between agents.
SED?
Full combination description CompareDXM + LSD, psilocybin, psilocin
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodFor this group, a direct toxic effect of the interaction on organs has not been established. Vomiting and effects on automatic body functions (autonomic effects) are possible [1, 8].
5HT-R
Full combination description CompareDXM + MDA, serotonergic cathinones, and other serotonergic releasers
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe group’s rating is based on extrapolation from the properties of its substances. The review separately discusses an MDMA study: its CYP2D6 findings concern MDMA and do not by themselves describe the other substances in this group.
REL · SYM
Full combination description CompareDXM + MDMA
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSerotonin-related effects and autonomic stress. In a human study, MDMA markedly changed DXM concentrations and metabolism. These findings are the basis for high confidence in direct evidence (D) [3].
REL · 2D6 · SYM
Full combination description CompareDXM + Memantine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOverlapping NMDA effects and long duration. Labeling notes lack of systematic assessment of the pair [14]
NMDA
Full combination description CompareDXM + Mescaline
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMore prominent nausea and autonomic stress [8].
5HT-R · SYM
Full combination description CompareDXM + Methadone
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSerotonergic effects [5] and respiratory effects [53]. Human findings are consistent with CYP2D6 inhibition by methadone [20]. The review table’s DXM + methadone row also lists “duration”, without specifying which effect’s duration the author means.
OP · SERT · 2D6 · CARD
Full combination description CompareDXM + Methamphetamine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodAutonomic and serotonergic stress. The review provides no measured severity of complications specifically from combining this substance with DXM.
SYM · REL
Full combination description CompareDXM + Methylene blue
intravenous
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodStrong inhibition of monoamine oxidase A (MAO-A), an enzyme that breaks down monoamines. The concern rests on the mechanism and the AUVELITY contraindication. Direct frequencies of outcomes with DXM are not given [2, 41].
MAO
Full combination description CompareDXM + Methylphenidate
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodPredominantly catecholaminergic effects.
SYM
Full combination description CompareDXM + Mirtazapine
No PHI rating
The review gives this DXM combination no PHI. Mirtazapine, buspirone, triptans and cyclobenzaprine differ in pharmacology and main concerns.
DXM + Moclobemide
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMoclobemide inhibits MAO-A. A small human study also found reduced DXM O-demethylation with unchanged DXO N-demethylation [43]. That study measured metabolism. Another source reports a fatal DXM–moclobemide overdose [27]. One such case cannot establish the frequency of complications during recreational use.
MAO · 2D6
Full combination description CompareDXM + Morphine, hydromorphone, oxycodone, heroin
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe main concerns involve breathing, consciousness and material entering the airways. These opioids differ from tramadol in their effects on serotonin reuptake [5].
OP · SED
Full combination description CompareDXM + Muscimol
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodGABA-A effects, impaired consciousness, material entering the airways [16]
SED
Full combination description CompareDXM + MXE and other ketamine analogues
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHeterogeneous group. Additional monoamine effects possible for some compounds
NMDA · MONO?
Full combination description CompareDXM + NBOMe compounds, including 25I, 25B, 25C
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodTheir own systemic toxicity, seizures, overheating. Additional DXM hazard inferred [15]
5HT-R · SYM · SEIZ
Full combination description CompareDXM + Nefazodone
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSerotonergic effects and CYP3A inhibition. Hepatotoxicity is described for nefazodone itself.
SERT · 5HT-R · 3A
Full combination description CompareDXM + Nicotine
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHeart rate, blood pressure and nausea. The FAQ includes reports of strong potentiation of DXM’s effects [1].
SYM
Full combination description CompareDXM + Nitrous oxide
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDissociation plus its own hypoxia hazards. Repeated use introduces a separate B12-related hazard [13]
NMDA · HYPOX · B12
Full combination description CompareDXM + Ondansetron
No PHI rating
Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31].
DXM + Other reversible MAO-A inhibitors
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMAO
Full combination description CompareDXM + Other strong CYP3A inhibitors, including cobicistat, azoles, clarithromycin
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodReduced processing through an alternative metabolic pathway. Effects differ across this group [24].
3A
Full combination description CompareDXM + PCP, 3-MeO-PCP, 3-HO-PCP, and related compounds
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHeterogeneous NMDA and additional effects. Autonomic stress and prolonged impairment
NMDA · SYM
Full combination description CompareDXM + Pethidine (meperidine)
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodIn cell tests with human transporters, pethidine (meperidine) inhibited serotonin reuptake [5]. The oral meperidine label describes respiratory depression and seizures associated with metabolite accumulation during prolonged use [52].
OP · SERT · SEIZ
Full combination description CompareDXM + Phenelzine, tranylcypromine, isocarboxazid
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSevere serotonin toxicity with combined MAO inhibition and effects on serotonin reuptake. Labels for DXM-containing medicines contraindicate concomitant use with MAOIs [2, 4]. A historical report describes a possible fatal reaction involving DXM and phenelzine [42].
MAO
Full combination description CompareDXM + Phenibut, baclofen
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodGABA-B effects alongside drowsiness. Direct DXM interaction insufficiently studied
SED
Full combination description CompareDXM + Piracetam, DMAE, and lecithin
No PHI rating
Piracetam, DMAE, and lecithin are excluded from the numerical matrix. The FAQ contains accounts of subjective memory improvement, but evidence is insufficient to treat them as protection against physical injury.
DXM + Pregabalin, gabapentin
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDrowsiness, impaired coordination. Respiratory concern increases with additional risk factors [12]
SED
Full combination description CompareDXM + Promethazine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodTherapeutic DXM combination and labeling. Drowsiness and reduced alertness, respiratory and anticholinergic concerns [33]
AM · SED
Full combination description CompareDXM + Pseudoephedrine, phenylephrine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodAdditional cardiovascular stress. PHI expresses the review’s comparative judgment; the author did not find a quantitative study of this combination.
SYM
Full combination description CompareDXM + QT-prolonging drugs
No PHI rating
Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31].
DXM + Quinidine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodDirect measurements concern how the body processes substances. Additional concerns about QT — an interval in the heart’s electrical cycle — and irregular heart rhythm depend on conditions [4, 19].
2D6 · CARD
Full combination description CompareDXM + Ritonavir
alone or in ritonavir-boosted regimens
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHuman tests that use substances to measure metabolic activity give different results across treatment regimens and measurements. They do not show a uniformly strong effect on the CYP2D6 enzyme [45, 46].
3A · 2D6
Full combination description CompareDXM + Salvinorin A (Salvia divinorum)
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSpecific toxic synergy not established. Functional impairment and secondary physical hazards [17]
KOR · IMP
Full combination description CompareDXM + Scopolamine
with known active-substance exposure
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodAntimuscarinic effects, overheating and impairment. Source [32] cited in this card describes antimuscarinic toxicity; the review uses that description to assess scopolamine.
AM · SED
Full combination description CompareDXM + Selegiline, rasagiline, and safinamide
with maintained MAO-B selectivity
No PHI rating
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44].
DXM + Selegiline or rasagiline
when MAO-B selectivity is lost
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMAO-A inhibition becomes relevant when selectivity is lost. This depends on the conditions of selegiline or rasagiline use [26, 34].
MAO
Full combination description CompareDXM + Sertraline, escitalopram, citalopram, fluvoxamine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSERT
Full combination description CompareDXM + St John’s wort
No PHI rating
The review leaves PHI unassigned for DXM with St John’s wort because data for a numerical comparison are insufficient. ACMT lists St John’s wort as a possible interacting agent, without a numerical estimate for this pair [25].
DXM + Tapentadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodOpioid effects plus demonstrated inhibition of serotonin and noradrenaline reuptake. The clinical contribution of the DXM interaction remains uncertain [5]
OP · SERT · SYM
Full combination description CompareDXM + Terbinafine
oral
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodA human study used a probe substance to assess CYP2D6 activity and showed inhibition by terbinafine [23]. High confidence in direct evidence (D) refers to that enzyme-test result. The test did not measure total DXM exposure over time (AUC) or clinical outcomes.
2D6
Full combination description CompareDXM + THC-dominant cannabis
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe main concerns involve heart rate, vomiting and coordination. Much of the stronger DXM effect mentioned in the review describes what users feel [1, 10].
CB · SYM · IMP
Full combination description CompareDXM + Tramadol
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodLaboratory findings of serotonergic effects [5] and tramadol prescribing-information warnings about respiratory depression and increased seizure risk [51].
OP · SERT · SEIZ
Full combination description CompareDXM + Trazodone
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSerotonergic effects, drowsiness and reduced alertness. PHI is the review’s comparative judgment; it provides no direct measurement of risk for this specific combination.
SERT · 5HT-R · SED
Full combination description CompareDXM + Clomipramine and other tricyclic antidepressants (TCAs)
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSERT · AM · CARD
Full combination description CompareDXM + triptans
No PHI rating
Triptans differ in pharmacology; the review leaves PHI unassigned for their DXM combinations. ACMT lists triptans as possible interacting agents, without numerical estimates for individual pairs [25].
DXM + tryptophan
No PHI rating
The review leaves PHI unassigned for DXM with tryptophan because data for a numerical comparison are insufficient.
DXM + Venlafaxine, desvenlafaxine
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodEffects on serotonin reuptake and noradrenergic stress. Limited direct evidence [2]
SERT · SYM
Full combination description CompareDXM + Yohimbine
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodThe rating is based on adrenergic stress. The Olney’s lesions hypothesis is part of the historical FAQ discussion [1, 21].
SYM
Full combination description CompareDXM + Zolpidem, zopiclone, and other Z-drugs
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodSedation and impaired consciousness; pharmacodynamic extrapolation
SED
Full combination description Compare